Taltz plus Zepbound shows broader biomarker changes than Taltz alone in psoriasis

On October 9, 2026 Lilly reported exploratory biomarker data from the TOGETHER-PsO Phase 3b trial, presented at Fall Clinical Dermatology. The analysis compared Taltz plus Zepbound with Taltz alone in adults with plaque psoriasis and obesity or overweight, and found broader psoriasis and metabolic biomarker changes in the combination group as early as week 12. The data are exploratory and have not yet been published in a peer-reviewed journal.

• Exploratory biomarker analysis from the TOGETHER-PsO Phase 3b trial
• Taltz plus Zepbound vs Taltz alone in plaque psoriasis with obesity or overweight
• Broader psoriasis and metabolic biomarker changes from week 12
• Detailed 36-week results planned for a peer-reviewed journal